Sequential homoharringtonine (HHT) and interferon (IFN-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML).

被引：0
|
作者：
O'Brien, S
Kantarjian, H
Koller, C
Andreeff, M
Feldman, E
Keating, M
Beran, M
Freireich, E
Rios, MB
Talpaz, M
机构：
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2707
引用
收藏
页码：656A / 656A
页数：1
相关论文
共 50 条
  • [31] DNA methylation of the protein-tyro sine phosphatase SHP1 in Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML).
    Hoshino, K
    Yang, H
    Canalli, AA
    Sanchez-Gonzalez, B
    Donato, N
    Kantarjian, H
    Issa, JP
    Garcia-Manero, G
    BLOOD, 2003, 102 (11) : 420A - 421A
  • [32] Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph(1)-positive chronic myelogenous leukemia
    Izumi, T
    Imagawa, S
    Hatake, K
    Miura, Y
    Ariyama, T
    Inazawa, J
    Abe, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1996, 64 (01) : 73 - 77
  • [33] Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
    Kantarjian, Hagop M.
    Shan, Jianqin
    Jones, Daniel
    O'Brien, Susan
    Rios, Mary Beth
    Jabbour, Elias
    Cortes, Jorge
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3659 - 3663
  • [34] IMATINIB MESYLATE INDUCES HIGH COMPLETE CYTOGENETIC AND MAJOR MOLECULAR RESPONSE RATES IN CHILDREN AND ADOLESCENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKAEMIA IN CHRONIC PHASE
    Giona, F.
    Putti, M. C.
    Santoro, N.
    Gottardi, E.
    Ladogana, S.
    Micalizzi, C.
    Iaria, G.
    Consarino, C.
    Burnelli, R.
    Rea, M.
    Nanni, M.
    Messina, C.
    Diverio, D.
    Biondi, A.
    Pession, A.
    Saglio, G.
    Foa, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 346 - 346
  • [35] The impact of cytogenetic clonal evolution (CgCE) on the therapeutic response (hematologic and cytogenetic response rates) to imatinib mesylate (IM) in the treatment of chronic myeloid leukemia (CML) Ph+
    Vargas-Viveros, P
    Hurtado-Monroy, R
    Cervera-Ceballos, E
    Viana-Alvarez, RM
    Rodriguez-Zulueta, P
    BLOOD, 2003, 102 (11) : 320B - 320B
  • [36] LEUKOCYTE INTERFERON TREATMENT EFFECT ON GRANULOCYTE MONOCYTE COLONY FORMING CELLS IN CHRONIC MYELOGENOUS LEUKEMIA PHILADELPHIA POSITIVE (CML PH1+) PATIENTS
    TALPAZ, M
    SPITZER, G
    HITTELMAN, W
    BERAN, M
    GUTTERMAN, JU
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 273 - 273
  • [37] PHILADELPHIA-CHROMOSOME (PH) NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH REARRANGEMENT OF THE BREAKPOINT CLUSTER REGION (BCR-POSITIVE) - UPDATE OF 23 PATIENTS
    CORTES, J
    KANTARJIAN, H
    OBRIEN, S
    BERAN, M
    ROBERTSON, L
    KURZROCK, R
    RIOS, M
    TALPAZ, M
    BLOOD, 1993, 82 (10) : A379 - A379
  • [38] Emergence of new clonal abnormalities (NCA) following interferon-alpha (IFN-A) complete cytogenetic response (CG-CR) in patients (pts) with chronic myelogenous leukemia (CML): Report of three cases.
    Fayad, L
    Kantarjian, H
    OBrien, S
    Seong, D
    Albitar, M
    Keating, M
    Talpaz, M
    BLOOD, 1996, 88 (10) : 929 - 929
  • [39] Long-term results of imatinib mesylate therapy in philadelphia chromosome (Ph) positive chronic phase chronic myelogenous leukemia (CML) post interferon-α (IFN) failure M.D.!Anderson experience in 261 patients.
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Verstovsek, S
    Faderl, S
    Rios, MB
    Shan, J
    Talpaz, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 588S - 588S
  • [40] Value of interphase fluorescent in situ hybridization (iFISH) studies in monitoring response to STI571 therapy in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    Kantarjian, HM
    O'Brien, S
    Hayes, KJ
    Glassman, AB
    Faderl, S
    Thomas, D
    Rios, MB
    Capdeville, R
    Talpaz, M
    BLOOD, 2000, 96 (11) : 255B - 255B
12345